ArticleSarcoma2020

Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023).

AeRang Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.